Key result
Patiromer prevents significant serum aldosterone increases vs placebo in patients with CKD and hyperkalemia.
Why the study?
Does patiromer reduce serum aldosterone and blood pressure in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors?
RCT (n=243)
randomized
Does patiromer reduce serum aldosterone and blood pressure in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors?
Absolute Event Rate: 0.23% vs 2.78%
Patiromer reduces serum potassium, aldosterone levels, and blood pressure independent of plasma renin activity in patients with CKD and hyperkalemia on RAAS inhibitors.
No takes yet. Share an insight, caveat, or question.
Patiromer sustains aldosterone, BP, and albuminuria reductions in hyperkalemic CKD on RAS inhibitors; confirms potassium lowering benefits independent of renin activity.
Weir et al. (2016) conducted an RCT in chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors (n=243). Patiromer vs. Placebo was evaluated on Mean change in serum aldosterone during the withdrawal phase (ng/dl). In patients with chronic kidney disease and hyperkalemia, patiromer sustained mean aldosterone levels (+0.23 ± 1.07 ng/dl) compared to significant increases with placebo (+2.78 ± 1.25 ng/dl).